CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

HP:0002383: EncephalitisHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1279 blood samples Wiki 1.00
drug505 Hydroxychloroquine Wiki 0.11

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D009410 Nerve Degeneration NIH 1.00
D004660 Encephalitis NIH 1.00
D003141 Communicable Diseases NIH 0.11
D007239 Infection NIH 0.07

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002180 Neurodegeneration HPO 1.00

There is one clinical trial.

Clinical Trials

1 Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection - MARNEVO-Covid

Emergence of Covid-19 virus is associated with high frequency of extremely severe clinical pictures, with minor signs of CNS impairment (e.g. anosmia, headache). Since neurotropism is a common feature of coronavirus infection in animals, the investigators examine if indirect signs of CNS lesion are observed in association with severe Covid-19 infection.

NCT04361344 COVID-19 Infection Encephalitis Biological: blood samples
MeSH:Infection Communicable Diseases Encephalitis Nerve Degeneration
HPO:Encephalitis Neurodegeneration

Primary Outcomes

Description: Change of neurofilament light chain (NFL) (pg/ml) level between first day of hospitalisation and one week; and change of GFAP (pg/ml) level between first day of hospitalisation and one week.

Measure: Change of neurodegeneration markers level

Time: Level of neurofilament light chain (NFL) is dosed at inclusion (day 0) and week 1. Level of GFAP is dosed at inclusion (day 0) and week 1 (day 7).

HPO Nodes